We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Phase 1 trial evaluates daratumumab efficacy after TBI-based conditioning in high-risk T-ALL/LLy, indicating potential treatment advances.
No takes yet. Share an insight, caveat, or question.
Quigg et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: